Importantly, this study offers a readily feasible strategy of molecular targeting of the LCOR/ERα axis using endocrine therapy and highlights potential future approaches leveraging LSKAA-encoding therapies to convert cold tumors into hot tumors, which is the overarching challenge in HR+ BC immunity and immunotherapy in these patients. This evidence concerns the gene LCOR and breast cancer.